| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1052916767 |
| P356 | DOI | 10.1007/S11882-015-0569-2 |
| P698 | PubMed publication ID | 26475526 |
| P50 | author | Whitney W. Stevens | Q102064075 |
| P2093 | author name string | Katherine N Cahill | |
| Kathleen Buchheit | |||
| P2860 | cites work | Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients | Q24555072 |
| Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes | Q24633568 | ||
| Platelets in patients with aspirin-exacerbated respiratory disease | Q28080840 | ||
| First complete description of the aspirin idiosyncrasy-asthma-nasal polyposis syndrome (plus urticaria)--1922 (with a note on aspirin desensitization). By F. Widal, P. Abrami, J. Lermoyez. | Q52401918 | ||
| Effect of aspirin desensitization on T-cell cytokines and plasma lipoxins in aspirin-exacerbated respiratory disease. | Q53058780 | ||
| Local increase in IgE and class switch recombination to IgE in nasal polyps in chronic rhinosinusitis. | Q54202786 | ||
| Clinical significance of immunoglobulin E responses to staphylococcal superantigens in patients with aspirin-exacerbated respiratory disease. | Q54657585 | ||
| Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients | Q66906547 | ||
| Aspirin-sensitive asthma: the effect of aspirin on the release of prostaglandins from nasal polyps | Q67596561 | ||
| Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma | Q72964940 | ||
| Anaphylactoid reactions due to nonsteroidal antiinflammatory drugs: clinical and cross-reactivity studies | Q73190469 | ||
| Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema | Q73784786 | ||
| Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association | Q73841819 | ||
| Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes | Q74551596 | ||
| Basophil responsiveness and clinical picture of acetylsalicylic acid intolerance | Q83366514 | ||
| Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis | Q84432107 | ||
| Evidence-based approach to aspirin desensitization in aspirin-exacerbated respiratory disease | Q38173911 | ||
| Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease. | Q38239473 | ||
| Omalizumab in asthma: an update on recent developments | Q38248469 | ||
| Recent advance in investigation of gene polymorphisms in Japanese patients with aspirin-exacerbated respiratory disease | Q38249919 | ||
| State of the art: a systematic review of the surgical management of aspirin exacerbated respiratory disease | Q38290525 | ||
| Cost of adult chronic rhinosinusitis: A systematic review | Q38339748 | ||
| Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD). | Q38348606 | ||
| NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity | Q38412095 | ||
| Aspirin desensitization for cardiovascular disease | Q38537673 | ||
| Factors associated with asthma control in patients with aspirin-exacerbated respiratory disease | Q41144370 | ||
| Diagnosis and management of rhinosinusitis: a practice parameter update | Q41726202 | ||
| Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)? | Q42456593 | ||
| Mediator release after nasal aspirin provocation supports different phenotypes in subjects with hypersensitivity reactions to NSAIDs. | Q42610937 | ||
| The A-444C polymorphism in the leukotriene C4 synthase gene is associated with aspirin-induced urticaria. | Q43253608 | ||
| Aspirin desensitization in patients undergoing planned or urgent coronary stent implantation. A single-center experience | Q43433421 | ||
| Cytokine expression before and after aspirin desensitization therapy in aspirin-exacerbated respiratory disease | Q43738554 | ||
| Characterization of aspirin allergies in patients with coronary artery disease | Q43747448 | ||
| Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease | Q43881393 | ||
| Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis | Q44432091 | ||
| The impact of endoscopic sinus surgery on health care use in patients with respiratory comorbidities | Q44531572 | ||
| Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics | Q44675978 | ||
| Association of thromboxane A1 synthase (TBXAS1) gene polymorphism with acute urticaria induced by nonsteroidal anti-inflammatory drugs | Q44682875 | ||
| Participation of prostaglandins in pathogenesis of aspirin-sensitive asthma | Q44965253 | ||
| The clinical dilemma of "silent desensitization" in aspirin-exacerbated respiratory disease | Q45390313 | ||
| Upregulation of CD63 or CD203c alone or in combination is not sensitive in the diagnosis of nonsteroidal anti-inflammatory drug intolerance. | Q45983722 | ||
| Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis. | Q45986027 | ||
| State of the Art: Medical treatment of aspirin exacerbated respiratory disease (AERD). | Q46165045 | ||
| Clinical course and urinary eicosanoids in patients with aspirin-induced urticaria followed up for 4 years | Q46325878 | ||
| Anaphylaxis to diclofenac: nine cases reported to the Allergy Vigilance Network in France | Q46339504 | ||
| Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily | Q46432280 | ||
| Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation | Q46711899 | ||
| Association analysis of FABP1 gene polymorphisms with aspirin-exacerbated respiratory disease in asthma | Q46814019 | ||
| Survey-Defined Patient Experiences With Aspirin-Exacerbated Respiratory Disease | Q48041264 | ||
| Sinonasal outcome under aspirin desensitization following functional endoscopic sinus surgery in patients with aspirin triad | Q48243802 | ||
| Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis | Q49046464 | ||
| Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma | Q49152600 | ||
| Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease | Q50439928 | ||
| Eosinophil activation and novel mediators in the aspirin-induced nasal response in AERD. | Q50891793 | ||
| Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. | Q51091863 | ||
| Aspirin 300 mg/day is effective for treating aspirin-exacerbated respiratory disease. | Q51194137 | ||
| An Hourly Dose-Escalation Desensitization Protocol for Aspirin-Exacerbated Respiratory Disease. | Q51603354 | ||
| Resolution of alcohol-induced respiratory symptoms following aspirin desensitization in aspirin-exacerbated respiratory disease. | Q51649409 | ||
| Aspirin exacerbated respiratory disease: the search for a biomarker. | Q51680404 | ||
| Treatment of aspirin exacerbated respiratory disease with a low salicylate diet: a pilot crossover study. | Q51688540 | ||
| Aspirin-exacerbated cutaneous disease (AECD) is a distinct subphenotype of chronic spontaneous urticaria. | Q51694726 | ||
| Elevated total serum IgE in nonatopic patients with aspirin-exacerbated respiratory disease. | Q51699073 | ||
| Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity. | Q51703960 | ||
| Aspirin sensitivity and IgE antibodies to Staphylococcus aureus enterotoxins in nasal polyposis: studies on the relationship | Q28167356 | ||
| Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis | Q28176722 | ||
| Mechanism of chronic urticaria exacerbation by aspirin | Q28181156 | ||
| Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease | Q28193148 | ||
| Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma | Q28193250 | ||
| The natural history and clinical characteristics of aspirin-exacerbated respiratory disease | Q28194291 | ||
| Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease | Q28194657 | ||
| Prevention and treatment of reactions to NSAIDs | Q28195570 | ||
| Skin tests in NSAIDS hypersensitivity | Q28200262 | ||
| Role of staphylococcal superantigen-specific IgE antibodies in aspirin-intolerant asthma | Q28201066 | ||
| Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease | Q28213966 | ||
| An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease | Q28219981 | ||
| Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs | Q28300126 | ||
| Aspirin activation of eosinophils and mast cells: implications in the pathogenesis of aspirin-exacerbated respiratory disease | Q30384450 | ||
| Hypersensitivity to Aspirin and other NSAIDs: Diagnostic Approach in Patients with Chronic Rhinosinusitis | Q30407185 | ||
| Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease | Q30410446 | ||
| Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program | Q30422401 | ||
| Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease | Q33598927 | ||
| Audit of nasal lysine aspirin therapy in recalcitrant aspirin exacerbated respiratory disease | Q33964973 | ||
| NSAID single-drug-induced reactions | Q34342618 | ||
| Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature | Q34441715 | ||
| A retrospective study of the clinical benefit from acetylsalicylic acid desensitization in patients with nasal polyposis and asthma | Q34707972 | ||
| The SNP rs3128965 of HLA-DPB1 as a genetic marker of the AERD phenotype | Q34764489 | ||
| A retrospective, cross-sectional study reveals that women with CRSwNP have more severe disease than men. | Q35285773 | ||
| Tolerance of daily low-dose aspirin does not preclude aspirin-exacerbated respiratory disease | Q35589545 | ||
| Flow Cytometry-Assisted Basophil Activation Test as a Safe Diagnostic Tool for Aspirin/NSAID Hypersenstivity | Q35895191 | ||
| Sex differences and sex steroids in lung health and disease | Q36003356 | ||
| Cytokines in Chronic Rhinosinusitis. Role in Eosinophilia and Aspirin-exacerbated Respiratory Disease | Q36128536 | ||
| Chronic rhinosinusitis with nasal polyps is characterized by B-cell inflammation and EBV-induced protein 2 expression | Q37090556 | ||
| Sinonasal outcomes after endoscopic sinus surgery in asthmatic patients with nasal polyps: a difference between aspirin-tolerant and aspirin-induced asthma? | Q37162102 | ||
| Effect of in vitro aspirin stimulation on basophils in patients with aspirin-exacerbated respiratory disease | Q37459192 | ||
| Safety of aspirin desensitization in patients with reported aspirin allergy and cardiovascular disease. | Q38044672 | ||
| Approach to patients with aspirin hypersensitivity and acute cardiovascular emergencies | Q38088786 | ||
| Unraveling the genetic basis of aspirin hypersensitivity in asthma beyond arachidonate pathways | Q38134073 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | anaphylaxis | Q168800 |
| aspirin | Q18216 | ||
| urticaria | Q187440 | ||
| polyposis | Q2103081 | ||
| asthma | Q35869 | ||
| P304 | page(s) | 69 | |
| P577 | publication date | 2015-12-01 | |
| P1433 | published in | Current Allergy and Asthma Reports | Q2246111 |
| P1476 | title | Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis | |
| P478 | volume | 15 |
| Q37692720 | Aspirin Intolerance: Experimental Models for Bed-to-Bench |
| Q49697163 | Expression of DACT1 in children with asthma and its regulation mechanism |
| Q50024380 | Orofacial manifestations of adverse drug reactions: a review study |
| Q38632809 | Pediatric Angioedema |
| Q38682358 | Practical Management of Patients with a History of Immediate Hypersensitivity to Common non-Beta-Lactam Drugs |
| Q90263644 | [Personalized medicine in allergology] |
Search more.